Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

Safety Profile in Patients with Chronic Lymphocytic Leukemia Undergoing Treatment with 1st and 2nd Generation Bruton Tyrosine Kinase Inhibitors: Multicentric Real-World Experience

Alberto Lopez Garcia, Alfonso Garcia, Ester Macia, Daniel Morillo, Carolina Miranda, Laura Bermejo, Maria Yuste, Maria Pilar Llamas Sillero, Raul Cordoba

Blood (2023) 142 (Supplement 1): 6551.

https://doi.org/10.1182/blood-2023-181722

Published: 2023

Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2023-182345

Published: 2023

Journal Articles

Comprehensive Geriatric Assessment and Geriatric Intervention in Older Patients with Newly Diagnosed Lymphoma: A Prospective Study

Alberto Lopez Garcia, Ana Isabel Hormigo, Ignacio Mahillo, Elham Askari, Daniel Morillo, Maria Angeles Perez Saez, Elena Prieto, Miriam Riesco, Celia Urrutia, Francisco Javier Martinez Peromingo, Juan Ignacio Gonzalez Montalvo, Raul Cordoba

Blood (2023) 142 (Supplement 1): 5146.

https://doi.org/10.1182/blood-2023-181652

Published: 2023

Journal Articles

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Blood (2023) 141 (17): 2114–2126.

https://doi.org/10.1182/blood.2022017333

Published: 2023

Includes: Supplemental data

Journal Articles

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Soraya Carrancio, Wen-Chi Chou, Alberto Risueño, Carla Guarinos, Gonzalo Lopez, Jean-Marie Michot, Loretta J. Nastoupil, Julio Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo Giles, Antonio Pinto, Danielle Greenawalt, Daniel W. Pierce, Michael Pourdehnad

Blood (2022) 140 (Supplement 1): 6455–6457.

https://doi.org/10.1182/blood-2022-159585

Published: 2022

Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Blood (2022) 140 (Supplement 1): 9454–9456.

https://doi.org/10.1182/blood-2022-167651

Published: 2022

Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan

Blood (2022) 140 (Supplement 1): 7284–7285.

https://doi.org/10.1182/blood-2022-159665

Published: 2022

Journal Articles

Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy

Blood (2022) 140 (Supplement 1): 5164–5166.

https://doi.org/10.1182/blood-2022-159076

Published: 2022

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 2606.

https://doi.org/10.1182/blood-2021-146987

Published: 2021

Journal Articles

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 161.

https://doi.org/10.1182/blood-2021-148813

Published: 2021

Journal Articles

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Blood (2021) 138 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2021-148723

Published: 2021

Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD

Blood (2019) 134 (Supplement_1): 4089.

https://doi.org/10.1182/blood-2019-125310

Published: 2019

Journal Articles

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Blood (2018) 132 (Supplement 1): 1493.

https://doi.org/10.1182/blood-2018-99-115849

Published: 2018

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria and Thrombosis Before and After Eculizumab

Cristina Muñoz-Linares, MD, Miguel Pastrana, MD, Emilio Ojeda, MD, PhD, Rafael Fores, MD, Martin Cabero, MD, Daniel Morillo, MD, Guiomar Bautista, MD, Belen Navarro, MD, Isabel Krsnik, MD, PhD, Santiago Gil, MD, PhD, Carmen Regidor, MD, PhD, Almudena de LaIglesia, MD, Jose Luis Bueno, MD, Jose A Garcia-Marco, MD, PhD, Jose Rafael Cabrera, MD, PhD

Blood (2013) 122 (21): 1242.

https://doi.org/10.1182/blood.V122.21.1242.1242

Published: 2013

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria and Cancer: High Incidence Of Cancer In a Large Series Of PNH Patients In a Single Center

Cristina Muñoz-Linares, MD, Emilio Ojeda, MD, PhD, Rafael Fores, MD, Martin Cabero, MD, Daniel Morillo, MD, Guiomar Bautista, MD, Belen Navarro, MD, Isabel Krsnik, MD, PhD, Santiago Gil, MD, PhD, Almudena de LaIglesia, MD, Carmen Regidor, MD, PhD, Jose Luis Bueno, MD, Jose A Garcia-Marco, MD, PhD, Jose Rafael Cabrera, MD, PhD

Blood (2013) 122 (21): 4871.

https://doi.org/10.1182/blood.V122.21.4871.4871

Published: 2013

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria and Magnetic Resonance Imaging

Miguel Pastrana, MD, Cristina Muñoz-Linares, MD, Emilio Ojeda, MD, PhD, Rafael Fores, MD, Beatriz Brea, MD, Martin Cabero, MD, Daniel Morillo, MD, Guiomar Bautista, MD, Belen Navarro, MD, Isabel Krsnik, MD, PhD, Almudena de LaIglesia, MD, Santiago Gil, MD, PhD, Carmen Regidor, MD, PhD, Jose Luis Bueno, MD, Jose A Garcia-Marco, MD, PhD, Jose Rafael Cabrera, MD, PhD

Blood (2013) 122 (21): 4873.

https://doi.org/10.1182/blood.V122.21.4873.4873

Published: 2013

Journal Articles

Analysis of Procoagulants Phospholipids in Plasma of Paroxysmal Nocturnal Hemoglobinuria Patients,Processed in Differents Preanalytic Conditions

Blood (2011) 118 (21): 5258.

https://doi.org/10.1182/blood.V118.21.5258.5258

Published: 2011

NARROW

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Safety Profile in Patients with Chronic Lymphocytic Leukemia Undergoing Treatment with 1st and 2nd Generation Bruton Tyrosine Kinase Inhibitors: Multicentric Real-World Experience

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Comprehensive Geriatric Assessment and Geriatric Intervention in Older Patients with Newly Diagnosed Lymphoma: A Prospective Study

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Paroxysmal Nocturnal Hemoglobinuria and Thrombosis Before and After Eculizumab

Paroxysmal Nocturnal Hemoglobinuria and Cancer: High Incidence Of Cancer In a Large Series Of PNH Patients In a Single Center

Paroxysmal Nocturnal Hemoglobinuria and Magnetic Resonance Imaging

Analysis of Procoagulants Phospholipids in Plasma of Paroxysmal Nocturnal Hemoglobinuria Patients,Processed in Differents Preanalytic Conditions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only